Handelsavisen
prelaunch
23
2342.T Tokyo Stock Exchange Department Stores

TransGenic Group Inc

¥221,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
0,5 %
ROE
0,7 %
Net margin
1,3 %
Debt / equity
0,39
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

TransGenic Group Inc operates in the retail sector, specifically in the department stores industry, generating revenue through the sale of consumer goods.

Business. TransGenic Group Inc (2342.T) is a department store retailer listed on the Tokyo Stock Exchange. The company operates within the Consumer Cyclicals sector, specifically focusing on the Department Stores industry. It generates revenue through product sales, with key performance indicators including same-store sales growth, traffic, and average ticket size. Specific details regarding operating segments and geographic mix are not available.

Classification92 %
SectorConsumer Cyclicals
Business sectorRetailers
IndustryDepartment Stores
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
0,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2342.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2342.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TransGenic Group Inc (2342.T) is a department store retailer listed on the Tokyo Stock Exchange. The company operates within the Consumer Cyclicals sector, specifically focusing on the Department Stores industry. It generates revenue through product sales, with key performance indicators including same-store sales growth, traffic, and average ticket size. Specific details regarding operating segments and geographic mix are not available.

    Classification92 %
    SectorConsumer Cyclicals
    Business sectorRetailers
    IndustryDepartment Stores
    AI synthesis
    GENERATED

    TransGenic Group Inc maintains a strong liquidity position with a current ratio of 2.69, indicating the company can cover its short-term liabilities more than two times over. The company holds JPY 2,478,229,000 in cash and equivalents, which is a significant portion of its total assets of JPY 9,810,999,000. However, the company reported negative operating cash flow of JPY -392,454,000, which may signal operational inefficiencies or capital investment pressures.

    In terms of profitability, TransGenic Group Inc has a return on equity (ROE) of 0.72% and a return on assets (ROA) of 0.43%, both of which are below the typical thresholds for strong performance in the retail sector. The company's operating income of JPY 15,328,000 is relatively low compared to its revenue of JPY 3,340,453,000, suggesting that the company is not generating substantial profit from its core operations.

    The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. This lack of geographic diversification may expose the company to regional economic fluctuations and regulatory changes. The company's revenue concentration in a single market could be a risk factor, especially in the context of the retail sector's sensitivity to consumer spending trends.

    Looking at the company's growth trajectory, the most recent actual revenue of JPY 13,005,130,000 is significantly lower than the reported revenue of JPY 3,340,453,000, indicating a potential discrepancy or a shift in reporting periods. The company's capital expenditure of JPY -265,668,000 suggests ongoing investment in infrastructure or expansion, which could be a positive sign for future growth. However, the negative operating cash flow may limit the company's ability to fund these investments internally.

    The risk assessment for TransGenic Group Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.39 is relatively low, suggesting a conservative capital structure. However, the negative operating cash flow and the need for capital expenditures may increase the company's reliance on external financing in the future.

    Recent events, including the company's financial performance and capital structure, suggest a mixed outlook. The company's ability to maintain its liquidity position while investing in growth will be critical for its long-term success. The company's financial health and strategic direction will need to be closely monitored to assess its ability to navigate the competitive retail landscape.

    Key takeaways
    • TransGenic Group Inc has a strong liquidity position with a current ratio of 2.69.
    • The company's profitability metrics, including ROE and ROA, are below typical thresholds for the retail sector.
    • Revenue is concentrated in the domestic market, which may expose the company to regional economic fluctuations.
    • The company's capital expenditure suggests ongoing investment in growth, but negative operating cash flow may limit internal funding.
    • Low liquidity and dilution risks are reported, with no immediate filing-based flags detected.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue grew at a 4.2% CAGR over four years, demonstrating consistent top-line expansion despite recent volatility.

    The company maintains a low debt-to-equity ratio of 0.39, indicating a conservative capital structure relative to peers.

    Dilution and liquidity risks are assessed as low, suggesting stable shareholder value and adequate market trading conditions.

    Net margin of 1.27% remains positive, showing the company retains some profitability despite operating losses in recent periods.

    Gross profit remained above 2.1 billion JPY in FY2025, indicating underlying product or service margins are still intact.

    BEAR CASE · 2

    Operating income turned negative at -616.7 million JPY in FY2025, reflecting a fundamental failure in core business operations.

    The company faces high credit risk, raising concerns about its ability to meet financial obligations and service existing debt.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-10
    Q4 2025 · Quarter highlights

    Revenue ¥3.47B, −0,7% YoY; Operating income −1 656,5% YoY.

    Revenue¥3.47B−0,7 % YoY
    Operating income-¥96.6M−1 656,5 % YoY
    Net income-¥1.5M+98,6 % YoY
    Free cash flow
    EPS
    Operating cash flow
    Financials
    Income statement
    Revenue¥3.47B
    Gross profit¥614.4M
    Operating income-¥96.6M
    Net income-¥1.5M
    Margins
    Gross margin17.7%
    Operating margin-2.8%
    Net margin-0.0%
    FCF margin
    Balance sheet
    Total assets¥10.34B
    Total liabilities¥5.40B
    Total equity¥4.94B
    Cash & equivalents¥2.24B
    Long-term debt¥2.89B
    P&L flow · revenue → net income
    Revenue ¥3.47BOperating costs ¥3.57BNet income ¥1.5M
    Highlights
    • Revenue ¥3.47B, −0,7% YoY
    • Operating income −1 656,5% YoY
    • Net income +98,6% YoY
    • Net margin -0.0%

    Valuation TTM

    Market price
    ¥221,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥5.89B
    Net cash
    ¥193.6M
    Current ratio
    2.7
    Debt / equity
    0.4
    ROA
    0.4%
    ROE
    0.7%
    Cash conversion
    -926.0%
    CapEx / revenue
    -8.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin0,5 %Below median
    Net Margin1,3 %Below median
    ROE0,7 %Below median
    Capex / Rev-8,0 %Bottom quartile
    D/E0,39Above median
    Cash Conv-9,26Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • TransGenic Group Inc Market data — financials · 2026-05-26
    • TransGenic Group Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2342.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-02-10 12:15 UTCEARNINGSQuarterly results — Q4 2025 Revenue JPY 3.47B · Net JPY -1.5M
    2025-11-12 12:15 UTCEARNINGSQuarterly results — Q3 2025 Revenue JPY 3.03B · Net JPY 2.6M
    2025-08-12 12:15 UTCEARNINGSQuarterly results — Q2 2025 Revenue JPY 3.20B · Net JPY 27.0M
    2025-06-16 12:15 UTCEARNINGSQuarterly results — Q1 2025 Revenue JPY 3.20B · Net JPY -798.0M
    2025-06-16 12:15 UTCEARNINGSAnnual results — FY 2025 Revenue JPY 13.01B · Net JPY -1.09B
    2025-02-14 12:15 UTCEARNINGSQuarterly results — Q4 2024 Revenue JPY 3.50B · Net JPY -109.4M
    2024-11-12 12:15 UTCEARNINGSQuarterly results — Q3 2024 Revenue JPY 3.43B · Net JPY -82.8M
    2024-08-09 11:45 UTCEARNINGSQuarterly results — Q2 2024 Revenue JPY 2.88B · Net JPY -99.4M
    2024-05-10 11:45 UTCEARNINGSQuarterly results — Q1 2024 Revenue JPY 3.34B · Net JPY 42.4M
    2024-05-10 11:45 UTCEARNINGSAnnual results — FY 2024 Revenue JPY 13.08B · Net JPY 4.1M
    2023-05-12 11:45 UTCEARNINGSAnnual results — FY 2023 Revenue JPY 11.43B · Net JPY -409.7M
    2022-05-13 11:45 UTCEARNINGSAnnual results — FY 2022 Revenue JPY 12.58B · Net JPY 1.88B
    2021-05-14 11:45 UTCEARNINGSAnnual results — FY 2021 Revenue JPY 11.05B · Net JPY 546.3M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage